Published online Jun 6, 2021. doi: 10.12998/wjcc.v9.i16.3814
Peer-review started: February 4, 2021
First decision: March 14, 2021
Revised: March 28, 2021
Accepted: April 29, 2021
Article in press: April 29, 2021
Published online: June 6, 2021
Processing time: 98 Days and 14.4 Hours
The coronavirus disease 2019 (COVID-19) pandemic imposed arestructuring of global health systems by rethinking spaces used for the care of these patients and the additions of intensive care, infectious diseases and pneumology departments. This paper provides evidence on the presence of severe acute respiratory syndrome coronavirus 2 in hepatocytes and its direct cytopathic activity, as well as the degree of liver damage due to drug toxicity, inflammation and hypoxia in COVID-19. A review of clinical trials has quantified liver damage through both pathology and biochemistry studies. Additionally, we briefly present the results of a study conducted in our clinic on 849 patients admitted for COVID-19 treatment, of which 31 patients had pre-existing chronic liver disease and 388 patients had values above the normal limit for alanine aminotransferase, aspartate aminotransferase, and total bilirubin. It was observed that patients with abnormal liver tests were significantly statistically older, had more comorbidities and had a higher percentage of unfavourable evolution (death or transfer to intensive care). The conclusion of this paper is that the main causes of liver damage are direct viral aggression, coagulation dysfunction and endothelial damage, and patients with impaired liver function develop more severe forms of COVID-19 which requires special care by a multidisciplinary team that includes a hepatologist.
Core Tip: The lung damage of these patients is primordial in the cascade of care that they receive, but also the liver damage induced by the direct action of the virus and the toxicity of the medication administered, has determined the active involvement of hepatologists in the care of these patients. The present paper aims to summarize the data published so far and personal experience, which may clarify the extent of liver damage in coronavirus disease 2019 and effective ways of therapeutic approach.